Bollard Group’s Charles River Laboratories CRL Stock Holding History

Bollard Group’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-15	Closed	-$3K	–	441
2023 Q2	$3K	Buy	+15	New	+$2.98K	﹤0.01%	463

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bollard Group's CRL Position: Q3 2023 in Review

Bollard Group sold out of Charles River Laboratories (CRL) in Q3 2023, closing a stake of 15 shares — an estimated $3K sold.

Bollard Group first reported a position in CRL in Q2 2023 and held it in 1 quarter. The position peaked at $3K in Q2 2023. 621 funds tracked by Wall St. Rank hold CRL as of Q3 2023.

Bollard Group reported no remaining Charles River Laboratories position as of Q3 2023 after selling out during the quarter.
Bollard Group sold 15 Charles River Laboratories shares in Q3 2023, an estimated $3K.
Bollard Group first reported a position in Charles River Laboratories in Q2 2023 and held it in 1 quarter.
Bollard Group's Charles River Laboratories position peaked at $3K in Q2 2023.
621 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2023.

Based on Bollard Group's 13F filing for Q3 2023, filed 14 Nov 2023.